Hawthorn executes deal with university
MADISON — Hawthorn Pharmaceuticals Inc. has struck a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer.
Under the terms of the agreement, Madison-based Hawthorn will receive an exclusive worldwide license to develop and commercialize the antibody portfolio.
“We are excited to be working with the world=-class cancer scientists at University of Pittsburgh’s Cancer Institute who have devoted their entire careers to improving people’s lives through cancer discovery,” said Rob Lewis, chief scientific officer at Hawthorn.
“There are many strengths created by our relationship with the University of Pittsburgh that promotes the rapid development of these novel antibodies,” said Max Draughn, president and CEO of Hawthorn. “Our collaboration is a shared vision to ultimately extend and improve the lives of many children and adults who suffer with various cancers.”
To sign up for Mississippi Business Daily Updates, click here.
FOLLOW THE MBJ ON TWITTERMy Tweets
Twang & Tourism: The Country Music Trail
Top Posts & Pages
- Officials set hunting dates for birds; expands dove season by 20 days
- Brandon man hauls in record 756-pound alligator
- Is cotton looking too good? Farmers facing weaker prices
- Woman found guilty of murder in buttocks injection case
- FLIPPING OUT — Flipping houses is popular in much of the country, but in Mississippi ...
- REVVING UP — Motorcars of Jackson is preparing to open its first-ever showroom on I-55
- Nehi Bottling Company has been a Cleveland fixture for 85 years
- Mississippi judge dismisses lawsuit seeking to overturn Sen. Cochran's GOP primary win
- Healthcare Marketplace to look much the same in 2015